Citius Pharmaceuticals (NASDAQ:CTXR) reported quarterly losses of $(0.02) per share. This is a 66.67 percent increase over losses of $(0.06) per share from the same period last year.
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces
